Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling